PE16299A1 - Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores - Google Patents

Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores

Info

Publication number
PE16299A1
PE16299A1 PE1997001069A PE00106997A PE16299A1 PE 16299 A1 PE16299 A1 PE 16299A1 PE 1997001069 A PE1997001069 A PE 1997001069A PE 00106997 A PE00106997 A PE 00106997A PE 16299 A1 PE16299 A1 PE 16299A1
Authority
PE
Peru
Prior art keywords
imidazolinilamino
formula
compounds
alpha
imidazolinylaminoindol
Prior art date
Application number
PE1997001069A
Other languages
English (en)
Inventor
Raymond Todd Henry
William Lee Seibel
Rusell James Sheldon
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE16299A1 publication Critical patent/PE16299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H o ALQUILO; R2, R3, R4, R5, R6 Y R7 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, OH, TIO, NITRO, CN, AMINO, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3 o HALOGENO; CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 SEA 2-IMIDAZOLINILAMINO; EL ENLACE (a) ES UN ENLACE SIMPLE O DOBLE; UN COMPUESTO (I) NO ES 4-(2-IMIDAZOLINILAMINO)INDOL; SIENDO COMPUESTOS (I) PREFERIDOS: 6-(2-IMIDAZOLINILAMINO)-7-METILINDOL Y 3-CIANO-6-(2-IMIDAZOLINILAMINO)-7-METILINDOL. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE: UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS SELECCIONADOS DE UN ANTIHISTAMINICO, UN ANTIINFLAMATORIO, 4-(2-IMIDAZOLINILAMINO)INDOL, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS DE ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE LA CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO Y ADICCION DE SUSTANCIAS, TRASTORNOS GASTROINTESTINALES, ULCERAS, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS
PE1997001069A 1996-11-25 1997-11-25 Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores PE16299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3177796P 1996-11-25 1996-11-25

Publications (1)

Publication Number Publication Date
PE16299A1 true PE16299A1 (es) 1999-03-12

Family

ID=21861336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001069A PE16299A1 (es) 1996-11-25 1997-11-25 Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores

Country Status (23)

Country Link
US (2) US6162818A (es)
EP (1) EP0944621B1 (es)
JP (1) JP2001506981A (es)
KR (1) KR100395356B1 (es)
CN (1) CN1092652C (es)
AR (1) AR013875A1 (es)
AT (1) ATE275142T1 (es)
AU (1) AU735767B2 (es)
BR (1) BR9713542A (es)
CA (1) CA2271841C (es)
CO (1) CO4910149A1 (es)
CZ (1) CZ180599A3 (es)
DE (1) DE69730516T2 (es)
ES (1) ES2225998T3 (es)
HU (1) HUP9904215A3 (es)
ID (1) ID22812A (es)
IL (1) IL130024A (es)
NO (1) NO992470L (es)
PE (1) PE16299A1 (es)
SK (1) SK68399A3 (es)
TR (1) TR199901885T2 (es)
WO (1) WO1998023610A1 (es)
ZA (1) ZA9710577B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
TR199901885T2 (xx) * 1996-11-25 1999-10-21 The Procter & Gamble Company Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri.
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
AU2042301A (en) * 1999-12-03 2001-06-12 Alcon Universal Limited 1-aminoalkyl-1H-indoles for treating glaucoma
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
NZ537200A (en) * 2002-06-24 2007-09-28 Schering Corp Indole piperidine derivatives useful as histamine H3 antagonists
KR20050072812A (ko) 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
CN101355876B (zh) 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
CL2008000838A1 (es) * 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100029662A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CH632268A5 (de) * 1977-01-14 1982-09-30 Sandoz Ag Verfahren zur herstellung von neuen heterocyclylaminoderivaten.
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
TR199901885T2 (xx) * 1996-11-25 1999-10-21 The Procter & Gamble Company Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri.

Also Published As

Publication number Publication date
HUP9904215A3 (en) 2002-01-28
EP0944621A1 (en) 1999-09-29
ID22812A (id) 1999-12-09
NO992470L (no) 1999-07-26
ES2225998T3 (es) 2005-03-16
US6395764B1 (en) 2002-05-28
TR199901885T2 (xx) 1999-10-21
IL130024A (en) 2002-12-01
CN1092652C (zh) 2002-10-16
KR20000069088A (ko) 2000-11-25
DE69730516D1 (de) 2004-10-07
ATE275142T1 (de) 2004-09-15
US6162818A (en) 2000-12-19
IL130024A0 (en) 2000-02-29
JP2001506981A (ja) 2001-05-29
AU735767B2 (en) 2001-07-12
AR013875A1 (es) 2001-01-31
AU5438098A (en) 1998-06-22
CO4910149A1 (es) 2000-04-24
DE69730516T2 (de) 2005-09-01
CN1238771A (zh) 1999-12-15
EP0944621B1 (en) 2004-09-01
HUP9904215A2 (hu) 2000-06-28
SK68399A3 (en) 2000-07-11
CA2271841C (en) 2003-07-08
NO992470D0 (no) 1999-05-21
KR100395356B1 (ko) 2003-08-21
WO1998023610A1 (en) 1998-06-04
CA2271841A1 (en) 1998-06-04
ZA9710577B (en) 1998-06-25
CZ180599A3 (cs) 1999-11-17
BR9713542A (pt) 2000-01-25

Similar Documents

Publication Publication Date Title
PE16299A1 (es) Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores
PE16399A1 (es) Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores
DK0771197T3 (da) Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
RS50437B (sr) Benzoilpirazoli i njihova primena u ulozi herbicida
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
PE20040840A1 (es) Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih
PE20010685A1 (es) Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20050867A1 (es) DERIVADOS DE PIPERAZINA COMO INHIBIDORES DE LA INTERACCION DE gp 120 CON CD4
NO20014529D0 (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
PE20030447A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol-3-il)-sustituidos y su obtencion
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
PE16599A1 (es) Compuestos de (2-imidazolinilamino) benzoxazol utiles como agonistas de alfa-2 adrenoreceptores
PE106299A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h-indol
BR0210170A (pt) Agente herbicida contendo benzoilpirazol e protetores
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
AR024840A1 (es) Compuestos de 5ht1 para terapia antidepresiva; composiciones farmaceuticas y su uso en la preparacion de medicamentos.
PE20061388A1 (es) Derivados de benzonitrilo como moduladores de androgeno
PE47099A1 (es) Compuestos de 2-imidazolinilaminoindazol utiles como agonistas de alfa-2 adrenoreceptores
PE20020436A1 (es) Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1)
PE109998A1 (es) Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa
ES2163730T3 (es) Derivados espirocetales y su uso como agentes terapeuticos.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE

Legal Events

Date Code Title Description
FX Voluntary withdrawal